Finasteride - Merck & Co.
Alternative Names: Anatine; Andozac; Avertex; Chibro-Proscar; Eutiz; Finasterin; Finastid; Jacarin; MK-0906; MK-906; Nasteril; Penester; Pro-Cure; Prodel; Propecia; Proscar; Prostene; Prosterid; Prostide; Tealep; YM-152Latest Information Update: 05 Nov 2023
At a glance
- Originator Merck & Co
- Class Androstenes; Antiacnes; Antiandrogens; Antineoplastics; Azasteroids; Skin disorder therapies; Small molecules
- Mechanism of Action Cholestenone 5 alpha-reductase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Alopecia; Benign prostatic hyperplasia
- No development reported Prostate cancer
Most Recent Events
- 27 May 2015 No recent reports of development identified - Phase-III for Prostate cancer (Prevention) in Canada and USA (PO)
- 05 Feb 2014 MSD Korea and Hanmi Pharmaceutical agree to co-promote finasteride in South Korea for Alopecia and Benign prostatic hyperplasia
- 01 Nov 2013 Merck discontinues the phase III trial in Benign prostatic hyperplasia in China (NCT01534351)